Annual Conference Programme Now Available
The draft programme for BTOG Annual Conference 2019 is now available to download.
PACIFIC Trial: Adjuvant Immunotherapy Improves Overall Survival (OS) in Stage III NSCLC
November 2018 By Fiona McDonald, Consultant Thoracic Clinical Oncologist The plenary session at WCLC 2018 in Toronto and parallel NEJM publication bring us the eagerly awaited overall survival results from the PACIFIC trial (NCT02125461). This was a randomised double-blind … Read More
Read our Latest E-News
We send a regular newsletter by email to those of our members who subscribe, click here to see the latest issue. Click here to join and subscribe and get your own BTOG E-News in your inbox.
WCLC Highlights
October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More
NELSON screening study gives boost to CT screening in Europe
September 2018 By Dr Matthew Callister, Consultant Respiratory Physician CT screening in Europe took a leap forward this week with the publication of the mortality results from the NELSON screening study. NELSON was a population-based controlled trial that ran in the … Read More
Immunotherapy for locally-advanced lung cancer one step nearer
August 2018 By Tom Newsom-Davis, Consultant Oncologist On 26th July 2018 one of the European Medicines Agency (EMA) committees recommended that the immunotherapy drug, Durvalumab, be licensed for use in patients with locally advanced (stage III) lung cancer. Although this does not mean … Read More